

21st January 2020

Our ref: FOI 03477

Dear

Thank you for your request for information.

**Your Request & Our Response**

I have a Freedom of Information request that I hope you'll be able to help me out with regarding the treatment of Lung and Melanoma patients.	
1. How many melanoma patients currently undergoing treatment are BRAF+ ?	There are currently no patients with malignant melanoma at BTH requiring systemic treatment, they are treated at Lancashire Teaching Hospitals.
2. In the past 3 months, how many melanoma patients were treated with the following: Bevacizumab Cobimetinib Dabrafenib Dabrafenib AND trametinib Dacarbazine Encorafenib AND binimetinib Ipilimumab Ipilimumab AND Nivolumab Nivolumab Pembrolizumab Trametinib Vemurafenib Vemurafenib AND Cobimetinib Other active systemic anti-cancer therapy Palliative care	Please see answer to Q1 above.
In the past 3 months how many patients were seen who had stage III resectable melanoma	Please see answer to Q1 above.

Chairman: Pearse Butler

Chief Executive: Kevin McGee (Interim)

**RESEARCH MATTERS AND SAVES LIVES - TODAY'S RESEARCH IS TOMORROW'S CARE**

Blackpool Teaching Hospitals is a Centre of Clinical and Research Excellence providing quality up to date care. We are actively involved in undertaking research to improve treatment of our patients. A member of the healthcare team may discuss current clinical trials with you.



Of all stage III patients seen, how many received a complete resection ?	Please see answer to Q1 above.
Of all stage III patients seen, how many were stage III a ?	Please see answer to Q1 above.
<p>3. Within your health trust how many patients are currently [within the past 3 months] being treated with the following for Non-small cell lung cancer (NSCLC )</p> <p>Afatinib          Alectinib          Atezolizumab + bevacizumab + carboplatin + paclitaxel          Atezolizumab mono          Bevacizumab          Brigatinib          Ceritinib          Crizotinib          Dacomitinib          Docetaxel monotherapy          Durvalumab          Erlotinib          Gefitinib          Gemcitabine          Necitumumab          Nintedanib with docetaxel          Nivolumab          Osimertinib          Paclitaxel          Pembrolizumab chemo in combination          Pembrolizumab monotherapy          Pemetrexed          Pemetrexed with carboplatin          Pemetrexed with cisplatin          Ramucirumab          Vinorelbine and cisplatin / carboplatin          Other active systemic anti-cancer therapy          Palliative care</p>	
Start Date	01/10/2019
End Date	31/12/2019
Diagnosis	Lung (NSCLC)
Name	Patients Treated
3-Weekly Carboplatin/weekly paclitaxel	2
Afatinib	8
Alectinib (NICE Blueteq)	2
Atezolizumab (Blueteq)	3
Atezolizumab Bevacizumab Carboplatin Paclitaxel (Blueteq)	1
Crizotinib (CDF Blueteq)	1
Docetaxel - 75mg/m2	2
Docetaxel/Nintedanib	3
Durvalumab NSCLC	1

Gefitinib	1
Nivolumab 240mg Flat Dose - (2years) (Blueteq)	6
Pembrolizumab Metastatic (3 weekly) (Blueteq)	38
Pembrolizumab Metastatic (6 weekly) (Blueteq)	4
Pembrolizumab, carboplatin and pemetrexed (CDF Blueteq)	22
Pemetrexed and Carboplatin	8
Pemetrexed and Cisplatin	1
Pemetrexed Maintenance (NICE Blueteq)	7
XALT3 Trial-Crizotinib	1
XALT3 Trial-X-396	1
Zoledronic Acid (3 weekly)	1

The information in this response is provided under the terms of the Open Government Licence. Please see here for more information:

<http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>

The following link is a customer satisfaction survey if you would like to leave feedback:

<http://www.bfwh.nhs.uk/our-services/hospital-services/information-governance/foi-questionnaire/>

If you are dissatisfied with our response to your request for access to information you may ask us to carry out an internal review. You should do this by writing to:

The Information Governance Manager  
 Blackpool Teaching Hospitals NHS Foundation Trust  
 Blackpool Victoria Hospital  
 Whinney Heys Rd  
 Blackpool  
 FY3 8NR  
 Email: [bfwh.pso@nhs.net](mailto:bfwh.pso@nhs.net)

If you remain unhappy, you may make a complaint to the Information Commissioner's Office.

Yours Sincerely,

Stephen Connor  
 Freedom of Information Manager